口服滔罗特预防保胆取石术后结石复发的临床观察

The study of taurolite on the relapse of cholelithiasis after gallbladder-protected lithotomy

目的评价选择性保胆取石术后口服牛磺熊去氧胆酸(滔罗特)预防胆囊结石复发的临床应用价值。方法统计2004年1月～2009年1月收治的保胆取石治疗胆结石患者共198例,均经微创保胆取石后保留功能良好的胆囊,其中40例术后间歇口服滔罗特;其余158例术后未服用药物。术后随访2年并统计分析以上胆结石患者症状改善情况和结石复发率。结果 198例保胆取石术均获成功,口服滔罗特患者2年后胆绞痛、右下腹不适和腹胀症状相比未服药者明显改善(P<0.05),术后2年服药组结石复发明显减少(P<0.05)。结论保胆取石术后患者口服滔罗特对胆囊结石的复发有预防作用。

[ Objective ] To evaluate the clinical application of tauro ursodeoxycholic acid （Taurolite） for preventing the relapse of lithiasis after the gallbladder-protected lithotomy. [Methods] There were 198 patients in our hospital who met the demand of lithotomy in protecting gallbladder. 40 cases were given tauro ursodeoxycholic acid （Taurolite） after surgery. The other 158 cases were given general treatment after surgery. The same nursing and diet therapies were given for the patients in the control group except for medication of the powder. All patients were followed up for more than 2 years and the gallbladder function, improvement of symptoms and the rate of the relapse of cholelithiasis were statistically analyzed. [Results ] All the operations of gallbladder-protected lithotomy for the198 patients were successful. No serious complication appeared. After two years, symptoms such as right lower abdominal discomfort and bloating significantly released in the patients take Taurolite, compared to those without medication （P 〈0.05）, and the relapse of lithiasis was decreased in the trail group （P 〈0.05）. [ Conclusion ] Application-of TUDCA for patients received gallbladder-protected lithotomy can prevent the relapse of cholelithiasis.